Table Info

Table 1.

Adverse events reported in clinical trials using PAMP-based adjuvants

Adjuvant	Composition	Vaccines	Adverse events
AS01	MPL and saponin	SUIVs—influenza (NCT03275389) [67]	Injection site pain, fatigue, headache, myalgia
		RSVPreF3—respiratory syncytial virus (NCT03814590) [68]	Injection site pain, fatigue, headache
		RTS,S/AS01—Malaria (NCT00866619) [69]	Fever, irritability, drowsiness, loss of appetite
		M72/AS01—tuberculosis (NCT01755598) [70]	Injection-site pain and influenza-like symptoms
AS04	MPL and alum	Cervarix^®—papillomavirus (approved vaccine) [71]	Injection site pain, redness and swelling, fatigue, gastrointestinal symptoms, headache
AS04	MPL and alum	Fendrix^®—hepatitis B (approved vaccine) [72]	Injection site pain, fatigue, headache, fever
CpG 1018	CpG oligodeoxynucleotides	HEPLISAV-B^®—hepatitis B (approved vaccine) [73]	Injection site pain, headache, fatigue
Alum/OMVs	Alum and OMVs from N. meningitidis	Soberana 01—COVID-19 (RPCEC00000338) [65]	Injection site pain and redness

SUIV: supra-seasonal universal influenza vaccines

Declarations

Author contribution

AIP: Conceptualization, Investigation, Writing—original draft. EDG: Conceptualization, Investigation, Supervision, Writing—review & editing.

Conflicts of interest

The authors have no conflicts of interest regarding the publication of this article.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), finance code [001], and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), grant number [18/04202-0]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

World Health Organization. Health emergencies list [Internet]. c2023 [cited 2023 Feb 09]. Available from: https://www.who.int/emergencies/situations

Li Q, Bergquist R, Grant L, Song JX, Feng XY, Zhou XN. Consideration of COVID-19 beyond the human-centred approach of prevention and control: the ONE-HEALTH perspective. Emerg Microbes Infect. 2022;11:2520–8. [DOI] [PubMed] [PMC]

Murray KA, Daszak P. Human ecology in pathogenic landscapes: two hypotheses on how land use change drives viral emergence. Curr Opin Virol. 2013;3:79–83. [DOI] [PubMed] [PMC]

El-Sayed A, Kamel M. Climatic changes and their role in emergence and re-emergence of diseases. Environ Sci Pollut Res Int. 2020;27:22336–52. [DOI] [PubMed] [PMC]

Link-Gelles R, Lutterloh E, Schnabel Ruppert P, Backenson PB, St George K, Rosenberg ES, et al.; 2022 U.S. Poliovirus Response Team. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater — New York, June–August 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1065–8. [DOI] [PubMed] [PMC]

Mercader-Barceló J, Otu A, Townley TA, Adepoju P, Walley J, Okoibhole LO, et al. Rare recurrences of poliomyelitis in non-endemic countries after eradication: a call for global action. Lancet Microbe. 2022;3:e891–2. [DOI] [PubMed]

Paniz-Mondolfi AE, Tami A, Grillet ME, Márquez M, Hernández-Villena J, Escalona-Rodríguez MA, et al. Resurgence of vaccine-preventable diseases in Venezuela as a regional public health threat in the Americas. Emerg Infect Dis. 2019;25:625–32. [DOI] [PubMed] [PMC]

de Oliveira IS, Cardoso LS, Ferreira IG, Alexandre-Silva GM, Jacob BdCdS, Cerni FA, et al. Anti-vaccination movements in the world and in Brazil. Rev Soc Bras Med Trop. 2022;55:e0592-2021. [DOI] [PubMed] [PMC]

Yang L, Grenfell BT, Mina MJ. Waning immunity and re-emergence of measles and mumps in the vaccine era. Curr Opin Virol. 2020;40:48–54. [DOI] [PubMed]

10.

Huang YJS, Higgs S, Vanlandingham DL. Emergence and re-emergence of mosquito-borne arboviruses. Curr Opin Virol. 2019;34:104–9. [DOI] [PubMed]

11.

Gonzalez-Perez M, Sanchez-Tarjuelo R, Shor B, Nistal-Villan E, Ochando J. The BCG vaccine for COVID-19: first verdict and future directions. Front Immunol. 2021;12:632478. [DOI] [PubMed] [PMC]

12.

Yitbarek K, Abraham G, Girma T, Tilahun T, Woldie M. The effect of Bacillus Calmette-Guérin (BCG) vaccination in preventing severe infectious respiratory diseases other than TB: implications for the COVID-19 pandemic. Vaccine. 2020;38:6374–80. [DOI] [PubMed] [PMC]

13.

Kulesza J, Kulesza E, Koziński P, Karpik W, Broncel M, Fol M. BCG and SARS-CoV-2—what have we learned? Vaccines (Basel). 2022;10:1641. [DOI] [PubMed] [PMC]

14.

Poland GA, Kennedy RB, Tosh PK. Prevention of monkeypox with vaccines: a rapid review. Lancet Infect Dis. 2022;22:e349–58. [DOI] [PubMed] [PMC]

15.

Shafaati M, Zandi M. State-of-the-art on monkeypox virus: an emerging zoonotic disease. Infection. 2022;50:1425–30. [DOI] [PubMed]

16.

Saadatian-Elahi M, Aaby P, Shann F, Netea MG, Levy O, Louis J, et al. Heterologous vaccine effects. Vaccine. 2016;34:3923–30. [DOI] [PubMed]

17.

Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20:375–88. [DOI] [PubMed] [PMC]

18.

Christensen JE, Thomsen AR. Co-ordinating innate and adaptive immunity to viral infection: mobility is the key. APMIS. 2009;117:338–55. [DOI] [PubMed]

19.

Mulder WJM, Ochando J, Joosten LAB, Fayad ZA, Netea MG. Therapeutic targeting of trained immunity. Nat Rev Drug Discov. 2019;18:553–66. [DOI] [PubMed] [PMC]

20.

Taks EJM, Moorlag SJCFM, Netea MG, van der Meer JWM. Shifting the immune memory paradigm: trained immunity in viral infections. Annu Rev Virol. 2022;9:469–89. [DOI] [PubMed]

21.

Sørup S, Villumsen M, Ravn H, Benn CS, Sørensen TIA, Aaby P, et al. Smallpox vaccination and all-cause infectious disease hospitalization: a Danish register-based cohort study. Int J Epidemiol. 2011;40:955–63. [DOI] [PubMed]

22.

Bottomley C, Bojang A, Smith PG, Darboe O, Antonio M, Foster-Nyarko E, et al. The impact of childhood vaccines on bacterial carriage in the nasopharynx: a longitudinal study. Emerg Themes Epidemiol. 2015;12:1. [DOI] [PubMed] [PMC]

23.

Sørup S, Benn CS, Poulsen A, Krause TG, Aaby P, Ravn H. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections. JAMA. 2014;311:826–35. [DOI] [PubMed]

24.

Lund N, Andersen A, Hansen ASK, Jepsen FS, Barbosa A, Biering-Sørensen S, et al. The effect of oral polio vaccine at birth on infant mortality: a randomized trial. Clin Infect Dis. 2015;61:1504–11. [DOI] [PubMed] [PMC]

25.

Düppre NC, Camacho LAB, da Cunha SS, Struchiner CJ, Sales AM, Nery JAC, et al. Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans R Soc Trop Med Hyg. 2008;102:631–8. [DOI] [PubMed]

26.

de Castro MJ, Pardo-Seco J, Martinón-Torres F. Nonspecific (heterologous) protection of neonatal BCG vaccination against hospitalization due to respiratory infection and sepsis. Clin Infect Dis. 2015;60:1611–9. [DOI] [PubMed]

27.

Biering-Sørensen S, Aaby P, Napirna BM, Roth A, Ravn H, Rodrigues A, et al. Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guérin vaccination at first health center contact. Pediatr Infect Dis J. 2012;31:306–8. [DOI] [PubMed]

28.

Arts RJW, Moorlag SJCFM, Novakovic B, Li Y, Wang SY, Oosting M, et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe. 2018;23:89–100.e5. [DOI] [PubMed]

29.

Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci U S A. 2020;117:17720–6. Erratum in: Proc Natl Acad Sci U S A. 2020;117:27741–2. [DOI] [PubMed] [PMC]

30.

Sato APS. Pandemic and vaccine coverage: challenges of returning to schools. Rev Saude Publica. 2020;54:115. [DOI] [PubMed] [PMC]

31.

Maltezou HC, Medic S, Cassimos DC, Effraimidou E, Poland GA. Decreasing routine vaccination rates in children in the COVID-19 era. Vaccine. 2022;40:2525–7. [DOI] [PubMed] [PMC]

32.

Pan American Health Organization. COVID-19 pandemic fuels largest continued backslide in vaccinations in three decades [Internet]. c2022 [cited 2023 Feb 01]. Available from: https://www.paho.org/en/news/15-7-2022-covid-19-pandemic-fuels-largest-continued-backslide-vaccinations-three-decades

33.

See KC. Vaccination for monkeypox virus infection in humans: a review of key considerations. Vaccines (Basel). 2022;10:1342. [DOI] [PubMed] [PMC]

34.

World Health Organization. Vaccines and immunization for monkeypox: interim guidance, 16 November 2022 [Internet]. c2023 [cited 2023 Feb 01]. Available from: http://www.who.int/publications/i/item/WHO-MPX-Immunization

35.

Ahmed SF, Sohail MS, Quadeer AA, McKay MR. Vaccinia-virus-based vaccines are expected to elicit highly cross-reactive immunity to the 2022 monkeypox virus. Viruses. 2022;14:1960. [DOI] [PubMed] [PMC]

36.

Gilchuk I, Gilchuk P, Sapparapu G, Lampley R, Singh V, Kose N, et al. Cross-neutralizing and protective human antibody specificities to poxvirus infections. Cell. 2016;167:684–94.e9. [DOI] [PubMed] [PMC]

37.

Gu X, Zhang Y, Jiang W, Wang D, Lu J, Gu G, et al. Protective human anti-poxvirus monoclonal antibodies are generated from rare memory B cells isolated by multicolor antigen tetramers. Vaccines (Basel). 2022;10:1084. [DOI] [PubMed] [PMC]

38.

Gushchin VA, Ogarkova DA, Dolzhikova IV, Zubkova OV, Grigoriev IV, Pochtovyi AA, et al. Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading monkeypox virus. Front Immunol. 2022;13:1023164. [DOI] [PubMed] [PMC]

39.

Panchanathan V, Chaudhri G, Karupiah G. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J Virol. 2006;80:6333–8. [DOI] [PubMed] [PMC]

40.

Panchanathan V, Chaudhri G, Karupiah G. Correlates of protective immunity in poxvirus infection: where does antibody stand? Immunol Cell Biol. 2008;86:80–6. [DOI] [PubMed]

41.

Amara RR, Nigam P, Sharma S, Liu J, Bostik V. Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol. 2004;78:3811–6. [DOI] [PubMed] [PMC]

42.

Kennedy RB, Poland GA. The identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins. Virology. 2010;408:232–40. [DOI] [PubMed] [PMC]

43.

Liu L, Zhong Q, Tian T, Dubin K, Athale SK, Kupper TS. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med. 2010;16:224–7. [DOI] [PubMed] [PMC]

44.

Tscharke DC, Karupiah G, Zhou J, Palmore T, Irvine KR, Haeryfar SM, et al. Identification of poxvirus CD8⁺ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med. 2005;201:95–104. [DOI] [PubMed] [PMC]

45.

Gillard GO, Bivas-Benita M, Hovav AH, Grandpre LE, Panas MW, Seaman MS, et al. Thy1⁺ NK cells from vaccinia virus-primed mice confer protection against vaccinia virus challenge in the absence of adaptive lymphocytes. PLoS Pathog. 2011;7:e1002141. Erratum in: PLoS Pathog. 2011;7. [DOI] [PubMed] [PMC]

46.

Arbel R, Sagy YW, Zucker R, Arieh NG, Markovits H, Abu-Ahmad W, et al. Vaccine effectiveness of modified vaccinia Ankara in human monkeypox. Res Sq [Preprint]. 2022 [cited 2023 Jan 30]. Available from: https://doi.org/10.21203/rs.3.rs-1976861/v1

47.

Fine PEM, Jezek Z, Grab B, Dixon H. The transmission potential of monkeypox virus in human populations. Int J Epidemiol. 1988;17:643–50. [DOI] [PubMed]

48.

Luciani L, Lapidus N, Amroun A, Falchi A, Souksakhone C, Mayxay M, et al. Orthopoxvirus seroprevalence and infection susceptibility in France, Bolivia, Laos, and Mali. Emerg Infect Dis. 2022;28:2463–71. [DOI] [PubMed] [PMC]

49.

Hazra A, Rusie L, Hedberg T, Schneider JA. Human monkeypox virus infection in the immediate period after receiving modified vaccinia Ankara vaccine. JAMA. 2022;328:2064–7. [DOI] [PubMed] [PMC]

50.

Payne AB, Ray LC, Cole MM, Canning M, Houck K, Shah HJ, et al. Reduced risk for mpox after receipt of 1 or 2 doses of JYNNEOS vaccine compared with risk among unvaccinated persons — 43 U.S. Jurisdictions, July 31–October 1, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1560–4. [DOI] [PubMed] [PMC]

51.

Blasi F, Gramegna A, Sotgiu G, Saderi L, Voza A, Aliberti S, et al. SARS-CoV-2 vaccines: a critical perspective through efficacy data and barriers to herd immunity. Respir Med. 2021;180:106355. [DOI] [PubMed] [PMC]

52.

Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem. 2013;8:360–76. [DOI] [PubMed]

53.

Grifoni A, Zhang Y, Tarke A, Sidney J, Rubiro P, Reina-Campos M, et al. Defining antigen targets to dissect vaccinia virus and monkeypox virus-specific T cell responses in humans. Cell Host Microbe. 2022;30:1662–70.e4. [DOI] [PubMed] [PMC]

54.

Gilchuk P, Hill TM, Guy C, McMaster SR, Boyd KL, Rabacal WA, et al. A distinct lung-interstitium-resident memory CD8⁺ T cell subset confers enhanced protection to lower respiratory tract infection. Cell Rep. 2016;16:1800–9. [DOI] [PubMed] [PMC]

55.

Heraud JM, Edghill-Smith Y, Ayala V, Kalisz I, Parrino J, Kalyanaraman VS, et al. Subunit recombinant vaccine protects against monkeypox. J Immunol. 2006;177:2552–64. [DOI] [PubMed]

56.

Goodridge HS, Ahmed SS, Curtis N, Kollmann TR, Levy O, Netea MG, et al. Harnessing the beneficial heterologous effects of vaccination. Nat Rev Immunol. 2016;16:392–400. [DOI] [PubMed] [PMC]

57.

Miyaji EN, Carvalho E, Oliveira MLS, Raw I, Ho PL. Trends in adjuvant development for vaccines: DAMPs and PAMPs as potential new adjuvants. Braz J Med Biol Res. 2011;44:500–13. [DOI] [PubMed]

58.

Munira SL, Hendriks JT, Atmosukarto II, Friede MH, Carter LM, Butler JRG, et al. A cost analysis of producing vaccines in developing countries. Vaccine. 2019;37:1245–51. [DOI] [PubMed]

59.

Luchner M, Reinke S, Milicic A. TLR agonists as vaccine adjuvants targeting cancer and infectious diseases. Pharmaceutics. 2021;13:142. [DOI] [PubMed] [PMC]

60.

Mekonnen D, Mengist HM, Jin T. SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways. Expert Rev Vaccines. 2022;21:69–81. [DOI] [PubMed] [PMC]

61.

Zhang N, Li K, Liu Z, Nandakumar KS, Jiang S. A perspective on the roles of adjuvants in developing highly potent COVID-19 vaccines. Viruses. 2022;14:387. [DOI] [PubMed] [PMC]

62.

Scaria PV, Rowe CG, Chen BB, Dickey TH, Renn JP, Lambert LE, et al. Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines. iScience. 2022;25:104739. [DOI] [PubMed] [PMC]

63.

Jangra S, Landers JJ, Rathnasinghe R, O’Konek JJ, Janczak KW, Cascalho M, et al. A combination adjuvant for the induction of potent antiviral immune responses for a recombinant SARS-CoV-2 protein vaccine. Front Immunol. 2021;12:729189. [DOI] [PubMed] [PMC]

64.

Xiao Y, Zeng Y, Alexander E, Mehta S, Joshi SB, Buchman GW, et al. Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge. Vaccine. 2013;31:319–26. [DOI] [PubMed] [PMC]

65.

Pérez-Rodríguez S, de la Caridad Rodríguez-González M, Ochoa-Azze R, Climent-Ruiz Y, Alberto González-Delgado C, Paredes-Moreno B, et al. A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: safety, reactogenicity and immunogenicity. Vaccine. 2022;40:2068–75. [DOI] [PubMed] [PMC]

66.

Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, et al.; HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:100–10. Erratum in: Lancet Oncol. 2012;13:e1. [DOI] [PubMed]

67.

Folschweiller N, Vanden Abeele C, Chu L, Van Damme P, García-Sastre A, Krammer F, et al. Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1–2 randomised controlled trial. Lancet Infect Dis. 2022;22:1062–75. Erratum in: Lancet Infect Dis. 2022;22:e159. [DOI] [PubMed]

68.

Leroux-Roels I, Davis MG, Steenackers K, Essink B, Vandermeulen C, Fogarty C, et al. Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase 1/2 randomized clinical trial. J Infect Dis. 2023;227:761–72. [DOI] [PubMed] [PMC]

69.

RTS,S Clinical Trials Partnership; Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012;367:2284–95. [DOI] [PubMed]

70.

Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, et al. Final analysis of a trial of M72/AS01_Evaccine to prevent tuberculosis. N Engl J Med. 2019;381:2429–39. [DOI] [PubMed]

71.

Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al.; GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757–65. [DOI] [PubMed]

72.

Tong NKC, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005;68:2298–303. [DOI] [PubMed]

73.

Halperin SA, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age. Vaccine. 2012;30:2556–63. [DOI] [PubMed]

74.

RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014;11:e1001685. [DOI] [PubMed] [PMC]